Terns Pharmaceuticals (NASDAQ:TERN) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Terns Pharmaceuticals (NASDAQ:TERN) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

TERN has been the topic of a number of other reports. William Blair upgraded Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, November 3rd. Oppenheimer boosted their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Barclays raised their price objective on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th. Finally, HC Wainwright raised their price target on Terns Pharmaceuticals from $20.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $55.56.

Terns Pharmaceuticals Trading Down 1.0%

Terns Pharmaceuticals stock opened at $36.60 on Friday. Terns Pharmaceuticals has a 12 month low of $1.87 and a 12 month high of $48.26. The business’s 50 day simple moving average is $34.51 and its 200 day simple moving average is $16.89. The company has a market cap of $3.30 billion, a price-to-earnings ratio of -35.53 and a beta of -0.28.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. As a group, equities research analysts forecast that Terns Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 1,155 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares of the company’s stock, valued at $1,942,578.05. The trade was a 2.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jill M. Quigley sold 24,520 shares of the stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 165,763 shares of company stock worth $5,752,450. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after purchasing an additional 770 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Terns Pharmaceuticals during the 4th quarter valued at about $80,000. The Manufacturers Life Insurance Company lifted its position in Terns Pharmaceuticals by 8.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,262 shares of the company’s stock worth $102,000 after buying an additional 2,097 shares during the last quarter. Velan Capital Investment Management LP boosted its stake in Terns Pharmaceuticals by 17.6% in the second quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock worth $75,000 after buying an additional 3,000 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in Terns Pharmaceuticals by 15.5% in the second quarter. Intech Investment Management LLC now owns 46,121 shares of the company’s stock worth $172,000 after buying an additional 6,199 shares in the last quarter. Institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.